MedTrace Logo

Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative

NCT00841516 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2013-11-08

No results posted yet for this study

Summary

This trial is performed for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen, rBet v1-FV

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

OTHER

Placebo

Placebo was given the same way as a subcutaneous (just under the skin) injection.

BIOLOGICAL

rBet v1-FV

Placebo was given the same way as a subcutaneous (just under the skin) injection.

Sponsors & Collaborators

  • Allergopharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Sabina Rak, Prof.Dr.med. · Prof. Dr. med. Rak

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-04-30
Completion
2013-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841516 on ClinicalTrials.gov